BioMarin Pharma (BMRN) Tops Q4 EPS by 37c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.43 -0.81%
Revenue Growth %: +32.7%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: +32.7%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.92, $0.37 better than the analyst estimate of $0.55. Revenue for the quarter came in at $747 million versus the consensus estimate of $711.42 million.
GUIDANCE:
BioMarin Pharma sees FY2025 EPS of $4.20-$4.40, versus the consensus of $4.16. BioMarin Pharma sees FY2025 revenue of $3.1-3.2 billion, versus the consensus of $3.1 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Hyperscale Data reports $0.95 net book value per share at June 30
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
